 HAYWARD, Calif., July 14, 2021 PRNewswire -- AcelRx Pharmaceuticals, Inc. Nasdaq: ACRX, AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced agreements with Laboratoire Aguettant Aguettant providing Aguettant with a license to commercialize DZUVEO in Europe, and providing AcelRx with two innovative pre-filled syringe product candidates for the U.S. Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. 